Nirmatrelvir / Ritonavir combo drug
Paxlovid is currently approved by FDA for emergency use authorization for the treatment of COVID-19. Nirmatrelvir is a SARS-CoV2 main protease inhibitor. Ritonavir is an HIV-1 Protease inhibitor and CYP3A inhibitor. This drug is administered orally.
Paxlovid is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Contraindications for Paxlovid include hypersensitivity to drug and in conditions where there is co-administration with drugs that are highly dependent on CYP3A for clearance, or with Potent CYP3A inducers.
Warnings and Precautions
• Hepatotoxicity
• HIV-1 Drug Resistance